Drug intelligence / Profile preview

gallium Ga 68 labeled PSMA-targeting radiodiagnostic agent HRS-9815

Development stage: Phase 1
Lead developer: Hengrui Pharmaceutical
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Gallium Ga 68 labeled PSMA-targeting radiodiagnostic agent HRS-9815 is a diagnostic radiopharmaceutical designed for PET/CT imaging. Upon intravenous administration, it targets and binds to prostate-specific membrane antigen (PSMA)-expressing tumor cells, enabling the detection of PSMA-positive lesions in patients with prostate cancer. The drug is being developed primarily for the diagnosis of prostate cancer using nuclear medicine techniques. It is currently in Phase I clinical trials to evaluate its safety, pharmacokinetics, and radiation dosimetry in adult patients with prostate cancer[1][2][4][7].

Other names: gallium Ga 68 labeled PSMA-targeting radiodiagnostic agent HRS-9815

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on gallium Ga 68 labeled PSMA-targeting radiodiagnostic agent HRS-9815.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on gallium Ga 68 labeled PSMA-targeting radiodiagnostic agent HRS-9815.

Explore the full profile